
Product Data Sheet

Product Name: ELOVL1-IN-1

Cat. No.: GC63493

Chemical Properties

Cas. No. 2227482-41-7

Formula $C_{18}H_{14}F_2N_4O$

M.Wt 340.33

Solubility DMSO : 100 mg/mL (293.83 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

ELOVL1-27 is an inhibitor of ELOVL fatty acid elongase 1 (ELOVL1; $IC_{50} = 900$ nM).¹ It reduces lysohexacosanoylphosphatidylcholine (LPC(C26:0)) synthesis in HEK293 cells ($IC_{50} = 13$ nM), as well as in primary fibroblasts isolated from patients with cerebral adrenoleukodystrophy (CALD) or adrenomyeloneuropathy (AMN; $IC_{50}s = 15-43$ nM), neurodegenerative diseases characterized by rapid inflammatory demyelination of the CNS. ELOVL1-27 (2, 16, and 32 mg/kg) reduces blood LPC(C26:0) levels in wild-type mice and rats. It also reduces CNS levels of LPC(C26:0) in an *ABCD1*^{-/-} mouse model of ALD when administered at a dose of 1 or 10 mg/kg per day for at least three months.

1. Come, J.H., Senter, T.J., Clark, M.P., et al. Discovery and optimization of pyrazole amides as inhibitors of ELOVL1. *Med. Chem.* 64(24)17753-17776(2021)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA